A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Public ClinicalTrials.gov record NCT05381909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
Study identification
- NCT ID
- NCT05381909
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2022
- Primary completion
- Jul 24, 2025
- Completion
- Jul 24, 2025
- Last update posted
- Feb 19, 2026
2022 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Md Anderson Cancer Center | Gilbert | Arizona | 85234-2165 | — |
| Florida Cancer Specialist (Scri) Sarasota | Sarasota | Florida | 34232 | — |
| Scri Florida Cancer Specialists North | St. Petersburg | Florida | 33705-1449 | — |
| Scri Florida Cancer Specialist East | West Palm Beach | Florida | 33401-3406 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-2013 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601-1915 | — |
| Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh | Pennsylvania | 15232-1309 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104-4663 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105-2108 | — |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390-7208 | — |
| The University of Texas Md Anderson Cancer Center (Department Gi Medical Oncology) | Houston | Texas | 77030-4000 | — |
| Intermountain Healthcare | Salt Lake City | Utah | 84143 | — |
| Next Virginia | Fairfax | Virginia | 22031 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05381909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2026 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05381909 live on ClinicalTrials.gov.